[go: up one dir, main page]

Passioura, 2005 - Google Patents

Identification of genes with N-ras modulatory function in haematopoietic cells

Passioura, 2005

View PDF
Document ID
8656280535818169800
Author
Passioura T
Publication year

External Links

Snippet

Identification of genes with N-ras modulatory function in haematopoietic cells Page 1 Identification of genes with N-ras modulatory function in haematopoietic cells Author: Passioura, Toby Publication Date: 2005 DOI: https://doi.org/10.26190/unsworks/6424 License …
Continue reading at unsworks.unsw.edu.au (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Ren Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Calabretta et al. The biology of CML blast crisis
Xie et al. Chronic myelogenous leukemia–initiating cells require Polycomb group protein EZH2
Scholl et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis
Gekas et al. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1
Hayashi et al. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
Nitulescu et al. Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation
Kim et al. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
Lacombe et al. Genetic interaction between Kit and Scl
Stavropoulou et al. A novel inducible mouse model of MLL-ENL-driven mixed-lineage acute leukemia
Quere et al. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation
Aikawa et al. Essential role of PU. 1 in maintenance of mixed lineage leukemia‐associated leukemic stem cells
Lynn et al. C-jun overexpressing CAR-T cells are exhaustion-resistant and mediate enhanced antitumor activity
Nakamura et al. NF-κB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression
Passioura Identification of genes with N-ras modulatory function in haematopoietic cells
Mehmetbeyoglu Duman Imbalance of DNA methylation and demethylation as pathogenic mechanism of acute leukaemia
Belenki Transcriptional control of cellular plasticity in cancer cell senescence
Van Thillo et al. Oncogenic cooperation in T-cell acute lymphoblastic leukemia: the role of TLX3 and TCF7-SPI1
Tonc Uncovering a MYC-Driven Tumor-Suppressive Program in Proliferating Lymphocytes
Santillan Functional specificity of the CBP domains in MLL-CBP induced immortalization
Gu The GAB2/SHP2 Pathway in BCR-ABL1-Induced Hematopoietic Neoplasia
Hasan JAK2V617F-positive Myeloproliferative Neoplasms: KI mouse models, interferon-α therapy and clonal architecture
Baumeister Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN)
Caeser Elucidating oncogenic mechanisms in human B cell malignancies
Rafiei The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia